header
Image from OpenLibrary

Risk adapted treatment for medulloblastoma In children / Soha Abdelrazek Abbas Ahmed ; Supervised Mohsen Samy Barsoum , Mohamed Saad Zaghloul , Alaa Mohamed Elhadded

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Soha Abdelrazek Abbas Ahmed , 2016Description: 173 P. : facsimiles ; 25cmOther title:
  • العلاج طبقا لمخاطر الورم الجزعى المخيخى فى الأطفال [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology - Radiation Summary: Medulloblastoma (MB) is one of the most common pediatric brain tumors. One hundred seventy five MB patients below the age of 18 years and less were classified into high risk, standered risk and infantile risk groups were enrolled in prospective study of risk adapted radiotherapy and chemotherapy treatment. They were treated at the radiation oncology department, children{u2019}s cancer hospital Egypt (CCHE), during the period from August 2009 to August 2015. Standard risk patients were randomized after surgery into either: Group A: Conformal craniospinal-irradiation (CSI) to 23.4Gray (Gy) and, intensity modulated radiotherapy (IMRT) boost to the whole posterior fossa (PF) up to a dose 55.8Gy. Group B: Conformal CSI to 23.4 Gy and IMRT Boost to the tumor bed (TB) dose up to 55.8Gy. The median follow up was 42 monthes, 4 years over all survival (OS) of high risk, standard risk and infantile risk group were 68.5+3.2%,82.1+6% and 67.3+6.9% respectively. Four years progression free survival (PFS) is 66.2+3.3, 79.8+4.3% and 67.3+6.9% respectively. The OS in standered risk group A, was 81.1+6%, and 84.7%+4.5 for Group B, (p=0.7). The EFS in group A, is 79.1%+6.3, and 84.1%+4.5 for group B (p=0.5). Post second cycle of cisplatine based maintenance chemotherapy, pure tone audiometry (PTA) showed 81.3% (13/16) grade3/grade 4 (G3/G4) sensory neural hearing loss (SNHL) in group A and (31.5%) 6/19 patients of group B, had SNHL hearing deterioration
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.06.Ph.D.2016.So.R (Browse shelf(Opens below)) Not for loan 01010110071226000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.06.Ph.D.2016.So.R (Browse shelf(Opens below)) 71226.CD Not for loan 01020110071226000

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology - Radiation

Medulloblastoma (MB) is one of the most common pediatric brain tumors. One hundred seventy five MB patients below the age of 18 years and less were classified into high risk, standered risk and infantile risk groups were enrolled in prospective study of risk adapted radiotherapy and chemotherapy treatment. They were treated at the radiation oncology department, children{u2019}s cancer hospital Egypt (CCHE), during the period from August 2009 to August 2015. Standard risk patients were randomized after surgery into either: Group A: Conformal craniospinal-irradiation (CSI) to 23.4Gray (Gy) and, intensity modulated radiotherapy (IMRT) boost to the whole posterior fossa (PF) up to a dose 55.8Gy. Group B: Conformal CSI to 23.4 Gy and IMRT Boost to the tumor bed (TB) dose up to 55.8Gy. The median follow up was 42 monthes, 4 years over all survival (OS) of high risk, standard risk and infantile risk group were 68.5+3.2%,82.1+6% and 67.3+6.9% respectively. Four years progression free survival (PFS) is 66.2+3.3, 79.8+4.3% and 67.3+6.9% respectively. The OS in standered risk group A, was 81.1+6%, and 84.7%+4.5 for Group B, (p=0.7). The EFS in group A, is 79.1%+6.3, and 84.1%+4.5 for group B (p=0.5). Post second cycle of cisplatine based maintenance chemotherapy, pure tone audiometry (PTA) showed 81.3% (13/16) grade3/grade 4 (G3/G4) sensory neural hearing loss (SNHL) in group A and (31.5%) 6/19 patients of group B, had SNHL hearing deterioration

Issued also as CD

There are no comments on this title.

to post a comment.